Showing 1 - 10 of 295
Persistent link: https://www.econbiz.de/10011981115
Persistent link: https://www.econbiz.de/10011983981
Persistent link: https://www.econbiz.de/10012112734
Standard measures of bodyweight (overweight and obese, for example) fail to reflect technological progress over time - and in particular, recent progress disproportionately promoting longevity at higher bodyweights (and differences in access to it). This paper builds on the pioneering work of...
Persistent link: https://www.econbiz.de/10012533362
This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of minimum efficacy standards and price control mechanisms (MES+PC). Through a...
Persistent link: https://www.econbiz.de/10012768128
This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of minimum efficacy standards and price control mechanisms (MES+PC). Through a...
Persistent link: https://www.econbiz.de/10012464081
The aim of this article is to analyze the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: Minimum Efficacy Standards (MES) and Price Controls (PC). We develop a model of adverse selection where a...
Persistent link: https://www.econbiz.de/10014212001
The aim of this article is to analyze the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: Minimum Efficacy Standards (MES) and Price Controls (PC). We develop a model of adverse selection where a...
Persistent link: https://www.econbiz.de/10005694983
Persistent link: https://www.econbiz.de/10003862258
Persistent link: https://www.econbiz.de/10003823019